Dasatinib is safe and effective in patients with previously untreated chronic myelogenous leukemia in chronic phase

被引：0
|
作者：
Quintas-Cardama, A.
Kantarjian, H.
OBrien, S.
Jones, D.
Borthakur, G.
Nicaise, C.
Cortes, J.
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0360
引用
收藏
页码：129 / 129
页数：1
相关论文
共 50 条
  • [31] Acute Myelogenous Leukemia Concurrent With Untreated Chronic Lymphocytic Leukemia
    Tsuyoshi Muta
    Takashi Okamura
    Yoshiyuki Niho
    International Journal of Hematology, 2002, 75 : 187 - 190
  • [32] Acute myelogenous leukemia concurrent with untreated chronic lymphocytic leukemia
    Muta, T
    Okamura, T
    Niho, Y
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 75 (02) : 187 - 190
  • [33] Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia
    Yim, Eunjung
    Choi, Yeon-Geun
    Nam, Yoon-Jeong
    Lee, Jain
    Kim, Jeong-A
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2018, 33 (02): : 446 - 448
  • [34] DASATINIB FRONTLINE IN ELDERLY PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA
    Stagno, F.
    Breccia, M.
    Annunziata, M.
    Trawinska, M.
    Iurlo, A.
    Sgherza, N.
    Fava, C.
    Gozzini, A.
    Luciano, L.
    Bonifacio, M.
    Sora, F.
    Crescenzi, S. Leonetti
    Bocchia, M.
    Crugnola, M.
    Gugliotta, G.
    Capodanno, I.
    Galimberti, S.
    Feo, C.
    Porrini, R.
    Pregno, P.
    Tiribelli, M.
    Rizzo, M.
    Mauro, E.
    Antolino, A.
    Rossi, A. Russo
    Guarini, A.
    Abruzzese, E.
    Vigneri, P.
    Latagliata, R.
    HAEMATOLOGICA, 2017, 102 : 90 - 91
  • [35] Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase
    Yasunobu Nagata
    Shiomi Fukuda
    Takeshi Kobayashi
    Takuya Yamashita
    Kazuteru Ohashi
    Hisashi Sakamaki
    Hideki Akiyama
    International Journal of Hematology, 2010, 91 : 539 - 541
  • [36] Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase
    Nagata, Yasunobu
    Fukuda, Shiomi
    Kobayashi, Takeshi
    Yamashita, Takuya
    Ohashi, Kazuteru
    Sakamaki, Hisashi
    Akiyama, Hideki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 91 (03) : 539 - 541
  • [37] A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL)
    Chen, Christine I.
    Paul, Harminder
    Snitzler, Susi
    Kakar, Sumeet
    Le, Lisa W.
    Wei, Ellen N.
    Lau, Anthea
    Johnston, James B.
    Gibson, Spencer B.
    Queau, Michelle
    Spaner, David
    Croucher, Danielle
    Sherry, Barbara
    Trudel, Suzanne
    LEUKEMIA & LYMPHOMA, 2019, 60 (04) : 980 - 989
  • [38] Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia
    Soumerai, Jacob D.
    Davids, Matthew S.
    Werner, Lillian
    Fisher, David C.
    Armand, Philippe
    Amrein, Philip C.
    Neuberg, Donna
    Hochberg, Ephraim P.
    Brown, Jennifer R.
    Abramson, Jeremy S.
    LEUKEMIA & LYMPHOMA, 2019, 60 (12) : 2931 - 2938
  • [39] Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
    Samimi, Sara
    Chu, Emily
    Seykora, John
    Loren, Alison
    Vittorio, Carmela
    Rook, Alain
    Rosenbach, Misha
    Kim, Ellen J.
    JAMA DERMATOLOGY, 2013, 149 (05) : 637 - 639
  • [40] Dasatinib-Induced Colitis in a Patient with Chronic Myelogenous Leukemia
    Perdigoto, David N.
    Lopes, Sandra
    Portela, Francisco
    Cipriano, Maria Augusta
    Tome, Luis
    GE PORTUGUESE JOURNAL OF GASTROENTEROLOGY, 2018, 25 (04) : 198 - 200
12345